Cancer is Curable: Indonesia’s New Healthcare Era Opens Doors for Medical Device Manufacturers
The landscape of oncology in Southeast Asia is shifting. For decades, a cancer diagnosis in Indonesia was often met with fear and a sense of finality. However, the Indonesian Ministry of Health is now championing a transformative message: cancer is curable. During the 2024 World Cancer Day commemorations at Dharmais Cancer Hospital, Health Minister Budi […]
The Evolution of Early Cancer Detection in Indonesia: Driving a New Era in Oncology Care
The landscape of oncology in Southeast Asia is undergoing a profound transformation, with Indonesia standing at the forefront of this shift. As of 2026, the Indonesian government has pivotally redefined its healthcare strategy, moving away from reactive late-stage treatment toward a proactive model centered on early cancer detection in Indonesia. This transition is not merely […]
The Future of Healthcare: Navigating Medical Device Regulatory Services in Indonesia in 2026
The Indonesian healthcare landscape is undergoing a monumental shift. Under the leadership of President Prabowo Subianto, the nation is moving away from a purely curative model toward a proactive, preventive health paradigm. Central to this transformation is the expansion of the Free Health Check (CKG) program, an ambitious initiative aiming to screen nearly half the […]
监管达尔文主义与印尼医疗保健市场：重新构建2026年医疗技术资本战略
Beyond the FDA and CE Mark: Why Early Market Entry in the World’s Fourth Most Populous Nation Can Strengthen Valuation and De-Risk Commercialization The 2026 Capital Environment: From Scientific Promise to Industrial Readiness Between 2020 and 2022, venture capital allocation into medical technology was heavily thesis-driven. A strong intellectual property portfolio, compelling preclinical data, and […]
高风险医疗器械注册指南：印尼3/D类标准与全球标准的对比
在印度尼西亚，高风险医疗器械的注册流程是东南亚最复杂的监管途径之一。对于全球制造商，尤其是那些生产C类、D类及高风险体外诊断产品的制造商而言，印度尼西亚已不再是边缘市场。它已成为一个具有自身监管逻辑、多层风险控制体系以及日益全球化趋势的战略目的地。[…]
风险与监管：为什么中国医疗器械制造商的信息必须非常详细才能在印度尼西亚注册？
The global medical device industry heavily relies on the supply chain originating from China. However, for distributors and importers in Indonesia, processing the Marketing Authorization for imported medical devices from China requires extreme precision, especially concerning the manufacturer’s identity and address. The common concern that many Chinese companies use Contract Manufacturers (CMs) has prompted regulators, […]
医疗器械清真审核：外国公司应该了解什么
对医疗器械而言，获得清真审核是印尼清真认证流程中最关键的步骤之一。对于外国制造商来说，审核阶段往往决定着产品能否快速获得批准，还是会面临代价高昂的延误、文件修改和漫长的验证周期。印尼的清真审核体系结构严谨、细致入微且监管严格，因此……
为什么清真认证对印尼医疗器械市场具有优势？
对于希望进入印尼市场的外国投资者和制造商而言，获得医疗器械清真认证不仅仅是监管上的必要条件，更是一项重要的战略商业优势。作为全球最大的穆斯林人口市场，印尼拥有亚洲增长最快的医疗保健行业之一，正朝着以清真认证为核心的医疗保健生态系统转型。
中国医疗器械注册：全球制造商完整指南
进入中国医疗器械市场需要遵守由国家药品监督管理局（NMPA）管理的规范化监管框架。国家药品监督管理局是中国医疗器械的中央主管机构，负责市场准入许可、上市后监管和维护国家技术标准。其技术评估机构——医疗器械评审中心（CMDE）负责开展科学评审[…]
在印度尼西亚保持医疗器械的清真合规性
对于进入印尼市场的外国医疗器械制造商而言，维持清真合规性是其最重要的上市后责任之一。获得清真认证固然是一个重要的里程碑，但真正的挑战才刚刚开始。印尼的《清真产品保证法》要求制造商在认证有效期过后，仍需确保原材料、生产流程和分销环节的持续完整性。[…]